Key Highlights

  • JIADE Limited (NASDAQ:JDZG) fell about 51% in a session. Published market data showed USD 0.776 on October 30, 2026 against a USD 1.59 prior close, and a USD 0.4549 quote on the November 2 screener, with a Market Value near USD 4.3 million.
  • Jaguar Health (NASDAQ:JAGX) fell about 49% to near USD 0.82 on November 2, 2026, which implies a prior close near USD 1.62, simple arithmetic, the day Series R Preferred Shares converted into five common shares each, capped at 11,625,000 conversion shares in total.
  • Estrella Immunopharma (NASDAQ:ESLA) fell 20.23% to USD 0.51. It had cash of USD 146,670 at June 30, 2026 against current liabilities of USD 9.3 million, and management cited substantial doubt about its ability to continue as a going concern.
  • Change Agents Corporation (NASDAQ:CHGA) fell 13.33% to USD 1.17 after stockholders approved all 17 proposals on October 30, 2026. It had about USD 172,000 of cash on September 11 and a USD 10 million Equity line.

1. JIADE Limited (NASDAQ:JDZG)

JIADE Limited (NASDAQ:JDZG), an education services Business based in Chengdu, Sichuan, fell about 51% in a session around the start of November. Two published readings disagree: USD 0.776 on October 30, down 51.19% from USD 1.59, and USD 0.4549 on the November 2 screener, down 51.42%, which implies a prior close near USD 0.94, simple arithmetic. Either two steep drops came in succession or one data set is stale. The latest company filing in published data is dated August 7, 2026, and no October or November announcement was found. A 1-for-25 reverse split took effect on March 23, 2026, followed by registered direct offerings of USD 3 million on February 18, up to USD 12.0 million on May 4 and USD 8.64 million around June 1. Nasdaq halted the shares from June 4 to July 31, 2026, with no reason published. With roughly 5.4 million shares outstanding, trading is thin and quoted moves can reverse. Short interest of about 102.6 thousand shares equaled 11.5% of shares outstanding. The 2024 initial public offering was priced at USD 4.00 a share.

2. Jaguar Health (NASDAQ:JAGX)

On October 2, 2026, Jaguar Health (NASDAQ:JAGX) announced a one-time Dividend of one Series R preferred share for each common share, designated at 2,325,000 shares. Each converts automatically into 5 common shares on November 2, subject to a 19.99% beneficial ownership cap, which raises the common share count without changing the company's value, though the company has not attributed the move to the conversion. The October 5 filing shows first monthly payments on two Royalty interests of USD 12 million original principal each, at least USD 750,000, pushed from October 1, 2026 to January 1, 2027, and a USD 6,220,812.50 note extended to the same date. A special meeting on November 6 includes a proposal to expand the equity plan share reserve six-fold, following an October 22 S-3 shelf filing. At under USD 1, Nasdaq minimum bid rules loom, and the October 28 filing announces no reverse split or new financing, so those remain unknown. The certificate carries no dividend or voting rights and a Liquidation preference of USD 0.0001 per share.

3. Estrella Immunopharma (NASDAQ:ESLA)

Estrella Immunopharma (NASDAQ:ESLA) is developing EB103, a cell therapy candidate in the Phase I/II STARLIGHT-1 trial for B-cell non-Hodgkin lymphoma, now at five sites. Cynthia Pussinen became chief executive and board chair effective October 25, 2026, with an option grant on 1,000,000 shares. That reshapes strategy but does not close the funding gap. Cash was about USD 1.9 million at March 31 after a USD 8.0 million January financing, then fell to USD 146,670 by June 30, so each new equity raise at a lower price means more shares per dollar. The company said no treatment-related serious adverse events occurred through the first month for the first patient treated with two infusions, a single-patient observation. Nasdaq set deadlines of February 16, 2027 for the USD 1.00 minimum bid price and March 1, 2027 for the USD 35 million market value standard. The stock rose 68.35% on October 14, fell 19.66% on October 15, and sits about 48% below a late-October quote near USD 0.985, simple arithmetic.

4. Change Agents Corporation (NASDAQ:CHGA)

Change Agents Corporation (NASDAQ:CHGA), formerly Avalon GloboCare, rebranded on July 21, 2026 as an agentic artificial intelligence software business. At the October 30 special meeting, holders approved raising authorized common stock from 100,000,000 to 125,000,000 shares, lifting the incentive plan reserve to 500,000 shares and issuances under Nasdaq Rule 5635(d), including a Hudson Global Ventures equity purchase agreement of up to USD 10,000,000. Those approvals remove a regulatory barrier to issuing large blocks of stock, which markets may read as dilution ahead. A 1-for-20 reverse split took effect on August 28, and the September prospectus reports no sustainable revenue, a six-month loss from continuing operations of about USD 6.56 million and about USD 5 million needed for 12 months. A fixed USD 2.00 put price sits above the USD 1.17 quote, so pricing terms matter and were not fully resolved. Plans include Beacon, a platform for visibility in AI search, and Catch-Up, an autonomous content tool, which have not shown revenue.

Where Things Stand

Yes, thin cash and rising share counts are the shared pattern, and none of the four has confirmed a November 2 cause. JIADE Limited (NASDAQ:JDZG) has conflicting price readings and a history of offerings. Jaguar Health (NASDAQ:JAGX) saw a mechanical conversion into five common shares per preferred share. Estrella Immunopharma (NASDAQ:ESLA) has very little cash and faces listing deadlines. Change Agents Corporation (NASDAQ:CHGA) has about one month of cash. The balance of evidence points to dilution and funding pressure rather than new bad news. Next dates include the November 6 meeting at Jaguar Health and the February and March 2027 Nasdaq deadlines at Estrella, and each of these carries risk.